HSHardiyanti Syarif

Hardiyanti Syarif

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hardiyanti Syarif has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Depression, Medication Adherence, and Beliefs as Determinants of Health-Related Quality of Life among People Living with HIV: A Cross-Sectional Pharmacoepidemiologic Study in Indonesia

    by Muh. Akbar Bahar, Hardiyanti Syarif, Neily Zakiyah, Najmiatul Fitria

    Objective: To examine the associations of depression, medication adherence, and medication beliefs with HRQoL among people living with HIV (PLWH) in primary healthcare (PHC) settings in Indonesia. Methods: This cross-sectional study included PLWH attending 6 PHCs in Makassar (July-September 2025). HRQoL was assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L); depression using the Patient Health Questionnaire-9 (PHQ-9); adherence using the Medication Adherence Report Scale (MARS); and beliefs using the Beliefs about Medicines Questionnaire (BMQ). Multivariable linear regression examined associations with HRQoL. Results: Among 400 participants (median age 30 years, interquartile range: 11), mean EQ-5D-5L utility was 0.94 ± 0.10. Higher depression severity was associated with lower HRQoL (β=−0.006; P < .001), while adherence and beliefs were not significant after adjustment. Conclusion: Depression was the only independent psychosocial predictor of HRQoL, highlighting the need for integrated mental health support in HIV care within PHC settings.

  • Open Access

    Ethanolic extract of Parkia speciosa Hassk leaves innovation of gastroretentive tablet: standardization and optimization

    by Nurfitriyana Nurfitriyana, Fitriya Fitriya, Najma Annuria Fithri, Dwi Kurnia Putri, Siti Marwah Lestari, Dyah Ayuwati Waluyo, Hardiyanti Syarif

    Parkia speciosa ethanol leaves extract contains flavonoid, tannin, and terpen as ulcus peptic remedy. These compounds exhibit limited activity in the stomach due to the short gastric residence time following oral administration. The formulation of gastroretentive tablets can overcome this limitation. This research aims to control the prolonged release of drugs in the stomach to increase bioavailability and characterize the ethanol leaves extract. Extraction was carried out by maceration using ethanol, followed by standardization based on specific and non-specific parameters extract. Gastroretentive tablet was formulated with combination of HPMC-K4M and chitosan using factorial design 22. Effects of compositional factors and their interactions on gastroretentive tablet was observed on hardness, friability, floating lag/duration time, swelling index, and mucoadhesive time. Results standardization extract showed that extract met the required criteria for both specific parameters (organoleptic properties and phytochemical screening) and non-specific parameters (moisture content, loss on drying, water/ethanol-soluble extract content). Based on with DX®10 analysis, the optimum formulation was achieved with 20.25% of HPMC-K4M and 10.26% of chitosan. The analysis of the optimum formulation characteristics was as follows: friability (0.22%), hardness (29.53 N), mucoadhesive time (22.86 hours), floating lag/duration time (27.54 minutes; 12 hours), and swelling index (312.82%). Result revealed that gastroretentive tablets formulated with ethanol extract of Parkia speciosa leaves improve gastric residence duration and promote better bioavailability.